In our last review of CRISPR Therapeutics (CRSP) on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses."




In our last review of CRISPR Therapeutics (CRSP) on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses."
As the action cools, there is going to be more concern about how easy it will be for this market to continue to rally at this pace.
Just when is the Federal Reserve going to reduce the cash slosh, anyway?
Let's look at breadth on the S&P 500, the put/call ratio, the bonds, the overbought market, and more.
Has this recent very powerful rally created a supply of underinvested bulls who are anxious to buy pullbacks and dips?
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login